Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263093 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01263093 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 47 participants.
The verdict
NCT01263093, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected.
Interventions
- DRUG Clopidogrel
- DRUG LY2216684
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263093
The ClinicalTrials.gov registry entry for NCT01263093 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT01263093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01263093 about?
NCT01263093 is a clinical study titled "A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel". The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occ...
What is the current status of trial NCT01263093?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2010-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01263093?
The interventions under investigation include: Clopidogrel (DRUG), LY2216684 (DRUG).
Who is sponsoring clinical trial NCT01263093?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.